Download PDF

1. Company Snapshot

1.a. Company Description

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide.It operates through Pharmaceuticals, Consumer Health, and Crop Science segments.The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy.


The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough.The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture.This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing.


The company has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc.for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases.It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers.


Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.

Show Full description

1.b. Last Insights on BAYN

Bayer's recent performance has been impacted by ongoing legal issues, including litigation costs related to its Roundup herbicide and other product liabilities. The company's Q4 2025 earnings call highlighted its efforts to address these challenges, while also delivering strong sales and earnings growth. Bayer's pharmaceutical division is a key growth driver, with a focus on areas such as oncology and cardiovascular care. The company has also announced leadership changes and plans to expand its U.S. manufacturing footprint. Additionally, Bayer has made progress in its pipeline, including the advancement of its AB-1002 study.

1.c. Company Highlights

2. Bayer's 2025 Financial Results: A Turnaround in Progress

Bayer reported sales of EUR 45.5 billion and core earnings per share of EUR 4.91 for 2025, within the improved guidance corridor. The company's free cash flow was EUR 2.1 billion. CEO Bill Anderson highlighted progress in the company's turnaround plan, with improvements in operations, launches, and resource allocation. The actual EPS came out at EUR 0.623 relative to estimates at EUR 0.3892, beating expectations. Group EBITDA before special items was EUR 9.7 billion, and core financial results improved markedly over the prior year.

Publication Date: Mar -05

📋 Highlights
  • 2025 Financial Performance:: Sales of EUR 45.5 billion and core earnings per share of EUR 4.91, aligning with guidance, with free cash flow of EUR 2.1 billion.
  • Organizational Savings:: Achieved EUR 2 billion in savings through the Dynamic Shared Ownership model, supporting operational efficiency.
  • Litigation Provisions:: Set aside EUR 11.8 billion for litigation-related liabilities, with 2026 expecting negative free cash flow due to payouts.
  • Divisional Growth Projections:: Crop Science (1-4% growth), Pharmaceuticals (50% growth for Nubeqa/Kerendia), and Consumer Health (0-4% growth) expected in 2026.
  • Debt and Ratings:: Net financial debt reduced below EUR 30 billion in 2025, targeting an A rating with leverage under 2.5; debt may rise in 2026 due to litigation.

Segment Performance

The company's divisions performed as follows: Crop Science progressed in its profitability improvement program, Pharmaceuticals had a rejuvenated picture with launch medicines driving growth, and Consumer Health maintained its bottom line despite market softness. Crop Science is focused on innovation, with a robust pipeline of crop protection products. Pharmaceuticals is expected to grow momentum for Nubeqa and Kerendia, with an expected growth of approximately 50% at constant currencies.

Litigation-Related Provisions and Liabilities

Bayer's litigation-related provisions and liabilities are based on a comprehensive assessment, with a provision of EUR 11.8 billion. The company expects a negative free cash flow in 2026 due to litigation-related payouts. CFO Wolfgang Nickl reported that the company's net financial debt was reduced below EUR 30 billion by the end of 2025.

Outlook for 2026

The company expects a solid performance in 2026, with product declines in Pharma and Crop Science offset by strong performance from launch products. Core earnings per share are expected to be roughly in line with last year. Analysts estimate next year's revenue growth at 2.7%. The company's guidance for 2026 includes net sales of EUR 45-47 billion, EBITDA before special items of EUR 9.6-10.1 billion, and core earnings per share of EUR 4.30-4.80.

Valuation Metrics

With a P/E Ratio of -185.57, P/B Ratio of 1.24, and EV/EBITDA of 11.55, the market seems to be pricing in the challenges Bayer is facing. The company's ROE is -0.64%, and Net Debt / EBITDA is 5.53, indicating a high level of debt. The Dividend Yield is 0.29%, and Free Cash Flow Yield is 10.72%. These metrics suggest that while the company is making progress in its turnaround plan, there are still challenges ahead.

Operational Efficiency

Bayer has reduced its workforce by around 14,000 jobs as part of its Dynamic Shared Ownership (DSO) program, aiming to increase efficiency and competitiveness. The company is focused on driving performance in its businesses rather than just reducing headcount.

Investment Plans

Bayer is making significant investments in Europe, including a new chemical research facility in Monheim and cell and gene therapy production in Berlin and San Sebastian. The company is also exploring opportunities in China, with five innovation hubs and over 100 collaborations with universities.

3. NewsRoom

Card image cap

ImmuCell Bolsters its Innovation Strategy with Appointments of Dr. Gilles Guillemette and Dr. Anthony DiMarco to the Board, and Moves to a Smaller Board of Independent Directors

Apr -13

Source: globenewswire.com

Card image cap

Nelson Ambrogio To Lead Bayer U.S. Pharma And Execution Focus

Apr -12

Source:

Card image cap

Is It Too Late To Consider Bayer (XTRA:BAYN) After Its 100% One Year Rebound?

Apr -11

Source:

Card image cap

OCT Europe 2026: tackling clinical trial complexities with innovation and partnerships

Apr -10

Source:

Card image cap

ezCater Rebrands to Reflect Expansion from Marketplace to Enterprise Workplace Food Platform

Apr -08

Source:

Card image cap

Regeneron Wins FDA Nod for Extended Eylea HD Dosing Interval

Apr -06

Source: zacks.com

Card image cap

Bayer Advances AB-1002 Study, Highlights Pharma Growth Strategy

Apr -02

Source:

Card image cap

Pediatric Neuroblastoma Treatment Market Outlook 2026-2030 & 2035 - United Therapeutics Corporation, APEIRON Biologics, Pfizer, Bayer, and Amgen Dominate

Apr -02

Source:

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (3.34%)

6. Segments

Crop Science

Expected Growth: 4.0%

Crop Science's 4.0 growth is driven by innovative solutions like precision farming, digitalization, and sustainable agriculture practices. Strong demand for food security and efficient resource use fuels growth. Bayer's robust pipeline of seeds, traits, and crop protection products, along with strategic acquisitions, also contribute to the segment's expansion.

Pharmaceuticals

Expected Growth: 2.5%

Bayer AG's pharmaceutical segment growth of 2.5% is driven by strong sales of key products like Xarelto and Eylea, as well as a robust pipeline of new medicines. Additionally, strategic acquisitions and partnerships have expanded its portfolio, contributing to revenue growth. Operational efficiencies and cost management have also supported the segment's performance.

Consumer Health

Expected Growth: 3.5%

Bayer AG's Consumer Health segment growth of 3.5% is driven by: strong demand for over-the-counter (OTC) medications, particularly pain relief and digestive health products; strategic acquisitions and partnerships; and increased focus on self-care and preventive healthcare. Expansion in emerging markets and digitalization of sales channels also contribute to growth.

All Other

Expected Growth: 1.5%

All Other segment growth at 1.5% driven by steady performance in Animal Health and Consumer Health businesses, with slight increase in Crop Science-related activities. Growth primarily attributed to strong sales in emerging markets and new product launches, offset by currency headwinds and competition.

Enabling Functions and Consolidation

Expected Growth: 0.0%

Bayer AG's Enabling Functions and Consolidation segment growth is driven by efficient resource allocation, streamlined operations, and synergies from integrating acquired businesses. The 0.0% growth rate suggests a stable segment, possibly due to optimization efforts and cost savings, which offset potential revenue increases, reflecting a strategic focus on consolidation and efficiency gains.

7. Detailed Products

Aspirin

A pain reliever and antipyretic medication

Xarelto

An oral anticoagulant medication

Xofigo

A radiopharmaceutical for the treatment of prostate cancer

Kogenate

A recombinant factor VIII for the treatment of hemophilia A

Crop Science Products

A range of crop protection products, seeds, and traits

Confidor

An insecticide for controlling pests in crops

Larvin

A biological insecticide for controlling pests in crops

Advantix

A topical insecticide and acaricide for dogs

Drontal

An anthelmintic for the treatment of parasitic infections in animals

8. Bayer Aktiengesellschaft's Porter Forces

Forces Ranking

Threat Of Substitutes

Bayer Aktiengesellschaft operates in a highly competitive industry, and there are many substitutes available for its products. However, the company's strong brand recognition and customer loyalty mitigate the threat of substitutes to some extent.

Bargaining Power Of Customers

Bayer Aktiengesellschaft's customers are largely fragmented and lack the bargaining power to negotiate prices or terms. The company's strong brand recognition and customer loyalty also reduce the bargaining power of customers.

Bargaining Power Of Suppliers

Bayer Aktiengesellschaft relies on a diverse range of suppliers for its raw materials and services. While some suppliers may have bargaining power, the company's scale and diversification of suppliers mitigate this risk.

Threat Of New Entrants

The pharmaceutical and life sciences industry has high barriers to entry, including significant research and development costs, regulatory hurdles, and the need for specialized expertise. This limits the threat of new entrants.

Intensity Of Rivalry

The pharmaceutical and life sciences industry is highly competitive, with many established players competing for market share. Bayer Aktiengesellschaft faces intense competition from rivals such as Pfizer, Novartis, and Roche.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 57.11%
Debt Cost 3.95%
Equity Weight 42.89%
Equity Cost 8.78%
WACC 6.02%
Leverage 133.16%

11. Quality Control: Bayer Aktiengesellschaft passed 1 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Novartis

A-Score: 6.5/10

Value: 3.0

Growth: 4.2

Quality: 8.3

Yield: 7.5

Momentum: 6.5

Volatility: 9.3

1-Year Total Return ->

View Full Report
Stock-Card
GSK

A-Score: 6.3/10

Value: 4.7

Growth: 2.2

Quality: 7.1

Yield: 6.9

Momentum: 9.0

Volatility: 7.7

1-Year Total Return ->

View Full Report
Stock-Card
Sanofi

A-Score: 5.9/10

Value: 6.2

Growth: 4.0

Quality: 8.0

Yield: 7.5

Momentum: 2.5

Volatility: 7.3

1-Year Total Return ->

View Full Report
Stock-Card
AstraZeneca

A-Score: 5.9/10

Value: 1.3

Growth: 7.6

Quality: 6.8

Yield: 3.1

Momentum: 9.0

Volatility: 7.3

1-Year Total Return ->

View Full Report
Stock-Card
Roche

A-Score: 5.4/10

Value: 1.1

Growth: 3.0

Quality: 6.4

Yield: 5.6

Momentum: 8.5

Volatility: 7.7

1-Year Total Return ->

View Full Report
Stock-Card
Bayer

A-Score: 4.4/10

Value: 7.0

Growth: 2.1

Quality: 2.7

Yield: 3.1

Momentum: 8.5

Volatility: 3.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

40.74$

Current Price

40.74$

Potential

-0.00%

Expected Cash-Flows